BGLAF (BioGaia AB) GF Value Rank: 9 (As of Jul. 04, 2026) — 29% Above Median


BGLAF BioGaia AB BGLAF
100 GF Score
Price $12.20
GF Value $12.51
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BioGaia AB GF Value Rank?

BioGaia AB BGLAF 100 GF Value Rank is 9 as of Jul. 04, 2026, which is 29% above its 10-year median of 7.00. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $12.51 (Fairly Valued). The stock has 5 warning signs investors should review.

BioGaia AB has the GF Value Rank of 9.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

BGLAF vs ZTS, UTHR: GF Value Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioGaia AB GF Value Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's GF Value Rank distribution charts can be found below:

* The bar in red indicates where BioGaia AB's GF Value Rank falls into.


BGLAF
100GF Score
BioGaia AB BGLAF
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 9 mean?
BioGaia AB (BGLAF) has a GF Value Rank of 9 as of Jul. 04, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on BioGaia AB and its competitors. This is 29% above median its historical median of 7.00. Over the past decade, BioGaia AB's GF Value Rank has ranged from 1.00 to 10.00.
Is BioGaia AB's GF Value Rank too high?
BioGaia AB's current GF Value Rank of 9 is 29% above median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, BioGaia AB has a GF Score™ of 100/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's GF Value Rank compare to ZTS and UTHR?
BioGaia AB's GF Value Rank of 9 can be compared against companies in the Drug Manufacturers industry. Historically, BioGaia AB's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Drug Manufacturers company?
A good GF Value Rank depends on the Drug Manufacturers industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on BioGaia AB and its competitors. BioGaia AB's current GF Value Rank is 9, which is 29% above median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BGLAF) is currently considered Fairly Valued. The stock's GF Value™ is $12.51, compared to a current price of $12.20 — trading 2.5% below its estimated fair value. The current GF Value Rank is 9, which is 29% above median its 10-year median of 7.00. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current GF Value Rank is 9 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioGaia AB (BGLAF) Overvalued in 2026?

Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued. The current stock price of $12.20 is trading 2.5% below its estimated GF Value™ of $12.51. GuruFocus considers BioGaia AB to be Fairly Valued.

Key valuation signals for BGLAF:

  • GF Value Rank: 9 (29% above median its 10-year median of 7.00)
  • GF Value™: $12.51 vs. price of $12.20 (2.5% below fair value)
  • GF Score™: 100/100 with 5 warning signs

No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioGaia AB Business Description

Address Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score

Get the complete analysis for BGLAF

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.20
Price
$12.51
GF Value